相关实验视频
Updated: Jan 12, 2026

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.5K
炎症性皮肤病中的全身Janus激酶抑制剂:一般医生的一本入门书
1FRACGP, PhD, MBBS, BSc (Hons 1),@Adjunct Lecturer, Department of General Practice,@Monash University,@ Melbourne, Vic; Research Fellow,@Department of Dermatology, Box Hill Hospital,@Melbourne, Vic.
Australian journal of general practice
|November 4, 2025
概括
一般医生应该了解Janus激酶 (JAK) 抑制剂用于治疗炎症性皮肤疾病,如亚托皮炎. 了解JAK/STAT路径和监测指南可以改善患者的护理.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性炎症疾病越来越多地使用新型的全身疗法来治疗.
- 简氏激酶 (JAK) 信号通路对于调解类型风湿性关节炎和炎症性肠病等疾病的炎症至关重要.
- 小分子JAK抑制剂对炎症性皮肤病,包括亚托匹性皮肤炎有前途.
研究的目的:
- 审查JAK/信号传感器和转录激活器 (STAT) 信号在阿托皮炎和其他炎症性皮肤疾病中的作用.
- 为全科医生提供有关慢性炎症性皮肤疾病新兴治疗方法的信息.
主要方法:
- 这是一个叙事评论.
- 在炎症性皮肤疾病中对JAK/STAT信号进行文献搜索.
- 对JAK抑制剂当前治疗结果和安全概况的分析.
主要成果:
- JAK/STAT通路的失调与亚托皮肤炎的发病有关.
- 雅克抑制剂为炎症性皮肤疾病提供了有针对性的治疗选择.
- 在临床研究中,已经观察到JAK抑制剂的有希望的结果.
结论:
- 了解JAK/STAT通路是管理炎症性皮肤疾病的关键.
- 对JAK抑制剂的风险和益处的全面了解对于安全有效的患者管理至关重要.
- 遵守监测指南将提高皮肤病治疗患者的治疗结果.
相关概念视频
The JAK-STAT Signaling Pathway
11.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.9K
Inflammatory Bowel Disease IV: Pharmacological Management
463
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
463
Skin Diseases and Disorders
5.1K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
5.1K
Rheumatic Heart Disease III: Medical Management
277
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
277
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
476
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
476
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475

